{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:50:53Z","timestamp":1790437853425,"version":"4.1.0"},"reference-count":4,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T00:00:00Z","timestamp":1635465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T00:00:00Z","timestamp":1635465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010481","name":"etablissement fran\u00e7ais du sang","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010481","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007525","name":"universit\u00e9 de rennes 1","doi-asserted-by":"publisher","award":["CFTR2 - COVID Fast Track Research Rennes"],"award-info":[{"award-number":["CFTR2 - COVID Fast Track Research Rennes"]}],"id":[{"id":"10.13039\/501100007525","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007525","name":"universit\u00e9 de rennes 1","doi-asserted-by":"publisher","award":["CFTR2 - COVID Fast Track Research Rennes"],"award-info":[{"award-number":["CFTR2 - COVID Fast Track Research Rennes"]}],"id":[{"id":"10.13039\/501100007525","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The SARS-CoV-2 virus is the causing agent of the Coronavirus disease 2019 (COVID-19) characterized by a huge pro-inflammatory response and coagulation disorders that may lead to for its severe forms, in organ failure or even death. As major players of thrombo-inflammation, platelets release large amounts of immunomodulatory molecules and regulate leukocyte and endothelial activity, which are both altered in COVID-19. Altogether, this makes platelets a very likely actor of the thrombo-inflammatory complications of COVID-19. Thus, we propose to identify a platelet inflammatory signature of severe COVID-19 specifically modulated throughout the course of the disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Luminex technology and enzyme-linked immunosorbent assay were used to assess plasma levels of platelet inflammatory markers in patients with severe acute respiratory syndrome coronavirus 2 infection on admission and for 14\u00a0days afterwards.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In accordance with the observations of other teams, we evidence that the plasma levels of the platelet soluble (s)CD40L is significantly elevated in the early stages of the disease. Interestingly we observe that the plasma level of sCD40L decreases overtime while that of sCD62P increases significantly.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our data suggest that there is a platelet signature of inflammatory response to SARS-COv-2 infection which varies overtime and could serve as monitoring biomarkers of patient inflammatory state.<\/jats:p><jats:p><jats:italic>Clinical trial registration number<\/jats:italic>: 2020-A01100-39; title: Human Ab Response &amp; immunoMONItoring of COVID-19 Patients, registration date: 05\/25\/2020; URL of the registry:<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/history\/NCT04373200?V_5=View\">https:\/\/clinicaltrials.gov\/ct2\/history\/NCT04373200?V_5=View<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12985-021-01680-3","type":"journal-article","created":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T11:02:59Z","timestamp":1635505379000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Platelet-derived sCD40L: specific inflammatory marker for early-stage severe acute respiratory syndrome coronavirus 2 infection"],"prefix":"10.1186","volume":"18","author":[{"given":"Hind","family":"Hamzeh-Cognasse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Reizine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Mismetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Gouin-Thibault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8041-928X","authenticated-orcid":false,"given":"Fabrice","family":"Cognasse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,29]]},"reference":[{"issue":"1","key":"1680_CR1","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1161\/ATVBAHA.120.314645","volume":"41","author":"I Portier","year":"2021","unstructured":"Portier I, Campbell RA. Role of platelets in detection and regulation of infection. Arterioscler Thromb Vasc Biol. 2021;41(1):70\u20138.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"1680_CR2","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1093\/infdis\/jit260","volume":"208","author":"P Damien","year":"2013","unstructured":"Damien P, Cognasse F, Lucht F, Suy F, Pozzetto B, Garraud O, et al. Highly active antiretroviral therapy alters inflammation linked to platelet cytokines in HIV-1-infected patients. J Infect Dis. 2013;208(5):868\u201370.","journal-title":"J Infect Dis"},{"issue":"2","key":"1680_CR3","doi-asserted-by":"publisher","first-page":"e3001109","DOI":"10.1371\/journal.pbio.3001109","volume":"19","author":"SP Comer","year":"2021","unstructured":"Comer SP, Cullivan S, Szklanna PB, Weiss L, Cullen S, Kelliher S, et al. COVID-19 induces a hyperactive phenotype in circulating platelets. PLoS Biol. 2021;19(2):e3001109.","journal-title":"PLoS Biol"},{"issue":"11","key":"1680_CR4","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1161\/CIRCRESAHA.120.317703","volume":"127","author":"Y Zaid","year":"2020","unstructured":"Zaid Y, Puhm F, Allaeys I, Naya A, Oudghiri M, Khalki L, et al. Platelets can associate with SARS-Cov-2 RNA and are hyperactivated in COVID-19. Circ Res. 2020;127(11):1404\u201318.","journal-title":"Circ Res"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-021-01680-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-021-01680-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-021-01680-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T01:42:31Z","timestamp":1726018951000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-021-01680-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,29]]},"references-count":4,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1680"],"URL":"https:\/\/doi.org\/10.1186\/s12985-021-01680-3","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,29]]},"assertion":[{"value":"30 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the local ethics committee (2020-A01100-39) with respect to the Declaration of Helsinki. Written informed consent was obtained from all the patients or their trusted persons. Data collection from the PLASMACOV cohort was approved by the French national ethics committee (2020-A00728-31).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"211"}}